Neurodegenerative conditions are a set of progressive and irreversible diseases that affect the structure and function of the brain, spinal cord, and nerves. These include Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, and amyotrophic lateral sclerosis (ALS). Over time, these diseases can cause changes in motor and cognitive functions, leading to a disruption of the activities necessary for daily life. Neurodegenerative disorders are caused by the degeneration of neurons, which are the nerve cells responsible for transmitting signals to the brain and the rest of the body. This loss of neurons leads to a disruption in communication, causing difficulty in movement and cognition. It can result in problems with memory, comprehension, problem-solving, and reasoning. It can also lead to difficulty in controlling movement, balance, and coordination. Risk factors for neurodegenerative diseases include age, genetics, and a history of head trauma. Neurodegeneration can also be the result of certain medical conditions such as diabetes, hypertension, and cardiovascular diseases. In addition, certain lifestyle factors such as smoking, lack of exercise, unhealthy diet, or excessive consumption of alcohol can all increase the risk of developing these conditions. Currently, the treatments available for neurodegenerative diseases are limited and focus primarily on managing the symptoms. Medication can provide relief from some of the physical and cognitive impairments, but it does not stop the progression of the disease. There is ongoing research to identify treatments that can slow the progression of the disease, as well as improve the quality of life for those living with these conditions.
Title : Atypical presentation of Juvenile myoclonic epilepsy in a 16-year-old female: A case report
George Diaz, Memorial Healthcare Systems, United States
Title : Triple-network dysfunction, ME/CFS, and the NeuroPhysics Treatment Process “A dynamical systems perspective on psychophysical organization and environmental interaction”
Ken Ware, NeuroPhysics Therapy Institute and Research Centre, Australia
Title : Beyond plaques: 10-nanometer-scale pathoconnectomics of Alzheimer’s disease
Ons M Saad, Panluminate Inc., United States
Title : Results from the global phase 3 trial (IB1001-303) evaluating levacetylleucine in children and adults with ataxia-telangiectasia
Chidinma Ejim, IntraBio, United States
Title : A phase 3, multinational, randomized, placebo-controlled, double-blind, crossover trial (IB1001-304) evaluating levacetylleucine in CACNA1A
Chidinma Ejim, IntraBio, United States
Title : Clinical and molecular phenotype of PTRHD1-associated juvenile parkinsonism
Bhavan A Modi, Barrow Neurological Institute at Phoenix Children's, United States